Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Medications For Heart Failure Market Grown from 2024 to 2025?

In recent times, the market size for heart failure medications has experienced considerable growth. A surge from $10.14 billion in 2024 to $10.90 billion in 2025, marking a compound annual growth rate (CAGR) of 7.4%, is projected. This past growth can be traced back to factors such as a heightened occurrence of cardiovascular diseases, augmented diagnosis and awareness initiatives, regulatory endorsements and backing, a rise in research and development expenditure for cardiovascular drugs, and the adoption of telemedicine and remote monitoring systems.

What Growth Rate Is Anticipated for the Medications For Heart Failure Market in the Coming Years?

A strong increase in market growth for heart failure medications is anticipated in the coming years, with the market predicted to ascend to $14.37 billion in 2029, boasting a compound annual growth rate (CAGR) of 7.2%. This projected growth within the forecast period can be traced back to factors such as the expansion of personalized and precision medicine, the escalating global prevalence of lifestyle diseases, an impressive pipeline of combination therapies and fixed-dose formulations, rising clinical proof and revised guidelines, and increasing urbanization. Noteworthy trends for the forecast period encompass the expansion of SGLT2 inhibitors, the integration of digital health, the advent of AI-powered analytics and remote monitoring tools, a growing emphasis on HFpEF treatment, and continuous research and development.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24315&type=smp

Who Are the Leading Companies in the Medications For Heart Failure Market?

Major companies operating in the medications for heart failure market are Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals Inc., Steris Pharma, CSPC Pharmaceutical, Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals, Ionis Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Hainan Poly Pharm. Co. Ltd., Addii Biotech, Lunan Pharmaceutical Group, Mylan Laboratories Inc., Neuracle Lifesciences Private Limited, JM Laboratories, Lexicon Pharmaceuticals.

What Are the Key Drivers of the Medications For Heart Failure Market?

The increasing number of cardiovascular diseases is anticipated to fuel the expansion of the market for heart failure medications. These ailments involve conditions affecting the heart and blood vessels, often leading to serious problems such as heart attacks and strokes. Sedentary lifestyles are one of the primary contributors to the rise in cardiovascular diseases as they gradually undermine the health of the heart and vessels. This consequent surge in cardiovascular diseases necessitates more competent treatments, which, in turn, encourages more investment in drugs for heart failure. As the disease becomes more rampant, pharmaceutical companies are giving much importance to the creation and improvement of treatments to effectively manage symptoms and improve patient outcomes. For instance, the Heart Failure Society of America (HFSA), a US-based organization of experts in heart failure, stated in September 2024 that about 6.7 million Americans aged 20 and above are currently living with heart failure (HF). The figure is feared to rise to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. Therefore, the increasing incidence of cardiovascular diseases is boosting the market growth of medications for heart failure.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24315&type=smp

What Are the Key Market Segments in the Medications For Heart Failure Industry?

The medications for heart failure market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Beta Blockers, Diuretics, Aldosterone Antagonists, Angiotensin II Receptor Blockers (ARBs), Other Drug Classes

2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril, Captopril, Perindopril, Other Angiotensin-Converting Enzyme (ACE) Inhibitors

2) By Beta Blockers: Carvedilol, Metoprolol Succinate, Bisoprolol, Nebivolol, Other Beta Blockers

3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics, Other Diuretics

4) By Aldosterone Antagonists: Spironolactone, Eplerenone, Other Aldosterone Antagonists

5) By Angiotensin II Receptor Blockers (ARBs): Valsartan, Losartan, Candesartan, Irbesartan, Other Angiotensin II Receptor Blockers (ARBs)

6) By Other Drug Classes: Angiotensin Receptor-Neprilysin Inhibitors, Ivabradine, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Hydralazine Or Isosorbide Dinitrate, Digoxin, Other Medications

What Are the Latest Trends in the Medications For Heart Failure Market?

Prominent businesses engaged in the heart failure medication market are concentrating on enhancing and developing innovative drugs like sodium-glucose cotransporter (SGLT) inhibitors. These innovative drugs target the glucose reabsorption process, resulting in better management of heart failure, improved efficiency, and superior cardiovascular health. Lexicon Pharmaceuticals, a biopharmaceutical firm based in the United States, launched Inpefa (sotagliflozin) in May 2023, which got the green light from the Food and Drug Administration (FDA). It is a once-daily oral pill that aims to decrease the chance of cardiovascular fatalities, hospitalization due to heart failure, and sudden heart failure visits in adults suffering from heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risks. Inpefa’s approval sets a new milestone for Lexicon as it is the first dual SGLT1/SGLT2 inhibitor in the market, expanding the treatment options for heart failure patients with various conditions.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/medications-for-heart-failure-global-market-report

What Are the Key Regional Markets in the Medications For Heart Failure Industry?

North America was the largest region in the medications for the heart failure market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medications for heart failure market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/customise?id=24315&type=smp

This Report Delivers Insight On:

1. How big is the medications for heart failure market, and how is it changing globally?

2. Who are the major companies in the medications for heart failure market, and how are they performing?

3. What are the key opportunities and risks in the medications for heart failure market right now?

4. Which products or customer segments are growing the most in the medications for heart failure market?

5. What factors are helping or slowing down the growth of the medications for heart failure market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model